NASDAQ:MGTXMeiraGTx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.07 +0.49 (+3.61 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$13.34Now: $14.07▼$14.1250-Day Range$11.59MA: $13.10▼$14.9352-Week Range$8.82Now: $14.07▼$22.99Volume55,494 shsAverage Volume115,984 shsMarket Capitalization$525.70 millionP/E RatioN/ADividend YieldN/ABeta1.49 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.67, MeiraGTx has a potential upside of 196.1% from its current price of $14.07.Amount of Analyst CoverageMeiraGTx has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesMeiraGTx has received 170 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMeiraGTx has received 120 “underperform” votes. (Add your “underperform” vote.)Community SentimentMeiraGTx has received 58.62% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote “Outperform” if you believe MGTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $667,887.00 in company stock.Percentage Held by InsidersOnly 16.50% of the stock of MeiraGTx is held by insiders.Percentage Held by Institutions52.53% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MeiraGTx are expected to decrease in the coming year, from ($2.01) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMeiraGTx has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTX Previous Symbol CUSIPN/A CIKN/A Webwww.meiragtx.com Phone646-860-7985Debt Debt-to-Equity Ratio0.10 Current Ratio5.83 Quick Ratio5.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.29 million Price / Sales39.56 Cash FlowN/A Price / Cash FlowN/A Book Value$5.22 per share Price / Book2.70Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-54,750,000.00 Net Margins-331.44% Return on Equity-29.99% Return on Assets-18.08%Miscellaneous Employees68 Outstanding Shares37,363,000Market Cap$525.70 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $14.07 +0.49 (+3.61 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MGTX News and Ratings via Email Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions How has MeiraGTx's stock price been impacted by Coronavirus? MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MGTX shares have decreased by 0.2% and is now trading at $14.07. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of MeiraGTx? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MeiraGTx. When is MeiraGTx's next earnings date? MeiraGTx is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for MeiraGTx. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings PLC (NASDAQ:MGTX) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.23. MeiraGTx had a negative return on equity of 29.99% and a negative net margin of 331.44%. View MeiraGTx's earnings history. What price target have analysts set for MGTX? 3 equities research analysts have issued 12 month price targets for MeiraGTx's shares. Their forecasts range from $40.00 to $45.00. On average, they expect MeiraGTx's share price to reach $41.67 in the next twelve months. This suggests a possible upside of 196.1% from the stock's current price. View analysts' price targets for MeiraGTx. What are Wall Street analysts saying about MeiraGTx stock? Here are some recent quotes from research analysts about MeiraGTx stock: 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (8/8/2020) 2. Chardan Capital analysts commented, "We rate MeiraGTx Buy on the forward- looking approach Meira management has taken to develop one of the broadest pipelines in all of AAV-based GT, including one with both lower-risk IRD opportunities for early wins and with higher-risk large-market opportunities that could generate profound investment returns." (9/23/2019) Has MeiraGTx been receiving favorable news coverage? Press coverage about MGTX stock has trended very positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MeiraGTx earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about MeiraGTx. Who are some of MeiraGTx's key competitors? Some companies that are related to MeiraGTx include SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Regenxbio (RGNX), Beam Therapeutics (BEAM), Adverum Biotechnologies (ADVM), I-Mab (BDTX) and Compugen (CGEN). View all competitors. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Novavax (NVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Corbus Pharmaceuticals (CRBP). Who are MeiraGTx's key executives? MeiraGTx's management team includes the following people: Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial OfficerMr. Micah Zajic, VP of Corp. Devel. When did MeiraGTx IPO? (MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager. What is MeiraGTx's stock symbol? MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX." Who are MeiraGTx's major shareholders? MeiraGTx's stock is owned by a number of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (9.94%), Alyeska Investment Group L.P. (1.79%), Prosight Management LP (1.39%), Rhenman & Partners Asset Management AB (0.80%), Bank of New York Mellon Corp (0.42%) and Goldman Sachs Group Inc. (0.18%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Stuart Naylor and Thomas E Shenk. View institutional ownership trends for MeiraGTx. Which institutional investors are selling MeiraGTx stock? MGTX stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Strs Ohio, and Marshall Wace LLP. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk. View insider buying and selling activity for MeiraGTx. Which institutional investors are buying MeiraGTx stock? MGTX stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Orbimed Advisors LLC, Bank of New York Mellon Corp, Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., Virtus ETF Advisers LLC, California Public Employees Retirement System, and Swiss National Bank. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive, and Nicole Seligman. View insider buying and selling activity for MeiraGTx. How do I buy shares of MeiraGTx? Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MeiraGTx's stock price today? One share of MGTX stock can currently be purchased for approximately $14.07. How big of a company is MeiraGTx? MeiraGTx has a market capitalization of $525.70 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. MeiraGTx employs 68 workers across the globe. What is MeiraGTx's official website? The official website for MeiraGTx is www.meiragtx.com. How can I contact MeiraGTx? MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
